Research Analysts’ Recent Ratings Updates for Foghorn Therapeutics (FHTX)
by Scott Moore · The Cerbat GemFoghorn Therapeutics (NASDAQ: FHTX) has recently received a number of price target changes and ratings updates:
- 10/2/2026 – Foghorn Therapeutics had its price target lowered by Guggenheim from $12.00 to $5.00. They now have a “buy” rating on the stock.
- 10/2/2026 – Foghorn Therapeutics was downgraded by Wedbush from “outperform” to “neutral”. They now have a $2.00 price target on the stock, down from $10.00.
- 10/2/2026 – Foghorn Therapeutics had its price target lowered by Guggenheim from $12.00 to $5.00. They now have a “buy” rating on the stock.
- 10/2/2026 – Foghorn Therapeutics had its price target lowered by HC Wainwright from $13.00 to $5.00. They now have a “buy” rating on the stock.
- 10/1/2026 – Foghorn Therapeutics was downgraded by TD Cowen from “buy” to “hold”.
- 10/1/2026 – Foghorn Therapeutics was downgraded by BTIG Research from “buy” to “neutral”.
- 10/1/2026 – Foghorn Therapeutics was downgraded by Citigroup Inc. from “market outperform” to “market perform”.
- 10/1/2026 – Foghorn Therapeutics was given a new $5.00 price target by Stifel Nicolaus.
- 10/1/2026 – Foghorn Therapeutics was downgraded by Citizens Jmp from “strong-buy” to “hold”.
- 9/17/2026 – Foghorn Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
Foghorn Therapeutics Inc is a clinical-stage biotechnology company focused on developing medicines that target the chromatin regulatory system, which helps control how genes are expressed. The company’s research is aimed primarily at cancer and other diseases in which abnormalities in gene regulation contribute to disease progression.
Foghorn uses its proprietary Gene Traffic Control platform to study interactions among chromatin-regulating proteins and identify potential drug targets.